Hutchison China Meditech Reports Positive Results From Kidney Cancer Drug Trial
February 14 2017 - 1:47AM
Dow Jones News
By Philip Waller
LONDON--Hutchison China MediTech Ltd (HCM.LN) on Tuesday
reported positive results from a Phase II trial of a kidney cancer
drug.
The group and its partner, AstraZeneca PLC (AZN.LN), said data
from the continuing trial of savolitinib in patients with papillary
renal cell carcinoma had shown early clinical benefit.
They said the data showed a clear efficacy signal and an
encouraging long duration of response to the drug, which remained
well tolerated.
Hutchison and AstraZeneca said the results supported initiation
of a Phase III trial.
-rite to Philip Waller at philip.waller@wsj.com
(END) Dow Jones Newswires
February 14, 2017 02:32 ET (07:32 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025
